Muscular Dystrophy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Muscular Dystrophy Pipeline Drugs Market Report Overview

Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker.  Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness, and progressive difficulty walking.

The report titled ‘Muscular Dystrophy –Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update’, provides an overview of the Muscular Dystrophy pipeline landscape. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects.

For more information on the muscular dystrophy pipeline drugs market overview, download free report sample

Muscular Dystrophy Pipeline Drugs Market Segmentation by Targets

The key targets of the muscular dystrophy pipeline drugs market are Mytotonin Protein Kinase, Double Homeobox Protein 4, Fukutin Related Protein, Polyadenylate Binding Protein 2, Calpain 3, Gamma Sarcoglycan, Glycogen Synthase Kinase 3 Beta, Growth/Differentiation Factor 8, Laminin Subunit Alpha 2, and RNA. In 2022, Myotonin Protein Kinase emerged as the most dominant target.

Muscular Dystrophy Pipeline Drugs Market Analysis by Targets, 2022 (%)

For additional insights on targets of the muscular dystrophy pipeline drugs market , request for a free sample report

Muscular Dystrophy Pipeline Drugs Market Segmentation by Mechanism of Actions

The key mechanism of actions of the muscular dystrophy pipeline drugs market are Double Homeobox Protein 4 Inhibitor, Myotonin Protein Kinase Inhibitor, Fukutin Related Protein Activator, Polyadenylate Binding Protein 2 Inhibitor, Calpain 3 Activator, Gamma Sarcoglycan Activator, Glycogen Synthase Kinase 3 Beta Inhibitor, Growth/Differentiation Factor 8 Inhibitor, Laminin Subunit Alpha 2 Activator, and Voltage Gated Sodium Channel Blocker. In 2022, Double Homeobox Protein 4 Inhibitor emerged as the leading mechanism of action.

Muscular Dystrophy Pipeline Drugs Market Analysis by Mechanism of Action, 2022 (%)

Download free sample report for more insights on the mechanism of action

Muscular Dystrophy Pipeline Drugs Market Segmentation by Route of Administration

The key route of administration in the muscular dystrophy pipeline drugs market are intravenous, oral, subcutaneous, intramuscular, parenteral, topical, and inhalational.

Muscular Dystrophy Pipeline Drugs Market Analysis by Route of Administration, 2022 (%)

For more insights on RoA of muscular dystrophy pipeline drugs market, download free report sample

Muscular Dystrophy Pipeline Drugs Market Segmentation by Molecule Types

The main molecule types in the muscular dystrophy pipeline drugs market are Small Molecule, Gene Therapy, Antisense Oligonucleotide, Monoclonal Antibody Conjugated, Antisense RNAi Oligonucleotide, Cell Therapy, Gene-Modified Cell Therapy, Monoclonal Antibody, RNAi Gene Therapy, and Synthetic Peptide. In 2022, small molecules were the most adopted molecule type in the muscular dystrophy pipeline drugs market.

Muscular Dystrophy Pipeline Drugs Market Analysis by Molecule Types, 2022 (%)

To know more about the molecule types, download free report sample

Competitive Landscape

Some of the leading companies in the muscular dystrophy pipeline drugs market are Sarepta Therapeutics Inc, Atamyo Therapeutics SAS, Myogem Health Company SL, Dyne Therapeutics Inc, Avidity Biosciences Inc, Vita Therapeutics Inc, AMO Pharma Ltd, Anima Biotech Inc, Edgewise Therapeutics Inc, Myocea Inc, and Pfizer Inc. In 2022, Sarepta Therapeutics Inc dominated the largest muscular dystrophy pipeline drugs market share with the greatest number of drugs pipeline.

Muscular Dystrophy Pipeline Drugs Market Analysis by Companies, 2022 (%)

For more information on leading companies, download a free sample report

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Muscular Dystrophy (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Muscular Dystrophy (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Muscular Dystrophy (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Muscular Dystrophy (Musculoskeletal Disorders)

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with a potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Muscular Dystrophy (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Muscular Dystrophy (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.